Is Tectonic Therapeutic, Inc. (TECX) a Buy, Sell, or Hold?
NASDAQ : TECX
Tectonic Therapeutic, Inc.
$32.6 USD
$1.95 (6.36%)
- Volume
- 277.61K
- Average Volume
- 208.35K
- Market Capitalization
- $615.14M
- P/E Ratio
- -7.31
- Dividend Yield
- 0.00%
- Price Target
- $78.00
- Year High
- $39.53
- Year Low
- $14.39
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $18.51
| Source | Headline |
|---|---|
|
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients
APEX 24-week Phase 2 trial is evaluating the safety and efficacy of TX45 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) APEX Phase 2 trial enrolled 191 patients across 14 countries, with approximately 72% of patients in the enriched population of CpcPH with a pulmonary vascular resistance (PVR) >3 WU at baseline TX45 APEX Phase 2 topline results expected in early Q1 2027 WATERTOWN, Mass. globenewswire.com - 2026-06-10 16:01:00 |
|
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients
WATERTOWN, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic” or the “Company”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today announced the completion of enrollment for the APEX trial, a 24-week Phase 2 clinical trial evaluating the safety and efficacy of TX45 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (“PH-HFpEF”). The trial was designed to include an enriched population of a more severe disease subtype of combined pre- and post-capillary pulmonary hypertension (“CpcPH”) patients with a pulmonary vascular resistance (“PVR”)> 3 Wood Units (“WU”) at baseline. globenewswire.com - 2026-06-10 16:01:00 |
|
Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights
WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic” or the “Company”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced financial results for the first quarter ended March 31, 2026, and provided an overview of recent business highlights. globenewswire.com - 2026-05-07 16:01:00 |
|
Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors
WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed Jessica Chutter to its Board of Directors, effective June 8, 2026. globenewswire.com - 2026-04-23 16:01:00 |
